Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AGE

AGE - AgeX Therapeutics Inc Stock Price, Fair Value and News

$0.500.00 (0.00%)
Market Closed

5/100

AGE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

5/100

AGE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.39

Target 3M

$0.44

Target 6M

$0.42

AGE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AGE Price Action

Last 7 days

4.2%

Last 30 days

2.0%

Last 90 days

-38.3%

Trailing 12 Months

-39.8%

AGE RSI Chart

AGE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AGE Valuation

Market Cap

5.3M

Price/Earnings (Trailing)

-0.29

Price/Sales (Trailing)

150.44

EV/EBITDA

0.02

Price/Free Cashflow

-0.32

AGE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.39

Target 3M

$0.44

Target 6M

$0.42

AGE Fundamentals

AGE Revenue

Revenue (TTM)

56.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

AGE Earnings

Earnings (TTM)

-18.6M

Earnings Growth (Yr)

-425.18%

Earnings Growth (Qtr)

29.05%

AGE Profitability

Operating Margin

28.57%

EBT Margin

-17898.21%

Return on Equity

-1.1K%

Return on Assets

-149.48%

Free Cashflow Yield

-309.71%

AGE Investor Care

Shares Dilution (1Y)

19.93%

Diluted EPS (TTM)

-0.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20242.4M1.6M830.3K56.0K
2023616.5K611.5K631.5K3.2M
2022255.9K367.8K479.6K591.5K
2021306.8K252.5K198.3K144.0K
20201.9M1.5M940.5K361.0K
20191.5M1.5M1.5M1.7M
20181.4M1.4M1.4M1.4M
20170001.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About AgeX Therapeutics Inc

AGE
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.
 CEO
 WEBSITEagexinc.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES5

AgeX Therapeutics Inc Frequently Asked Questions

AGE is the stock ticker symbol of AgeX Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of AgeX Therapeutics Inc is 5.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AGE's fair value in chart for subscribers.

The fair value guage provides a quick view whether AGE is over valued or under valued. Whether AgeX Therapeutics Inc is cheap or expensive depends on the assumptions which impact AgeX Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGE.

As of Wed Jan 28 2026, AGE's PE ratio (Price to Earnings) is -0.29 and Price to Sales (PS) ratio is 150.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGE PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, AgeX Therapeutics Inc has provided -0.181 (multiply by 100 for percentage) rate of return.